Taking COVID Research Out of the Clinic and into the Home:

Early Insights on a Virtual Interventional Trial

The level of patient monitoring needed to support a COVID-19 trial has typically only been achieved in hospitals. Enter decentralized clinical trials. DCTs can take symptomatic patients with COVID19, who are recovering at home, and involve them in a safe and effective remote study. In this presentation, we are joined by client RedHill Biopharma to detail insights from our pioneering interventional COVID-19 DCT utilizing integrated digital devices, next-gen ePRO, telehealth, and in-home visits by HCPs.

Interested in Viewing the Webinar?

Fill out the form below for access.

Virtual Trial Journey

A Seamless End-to-End Experience

ObvioHealth studies are run on our purpose-built platform by our own in-house virtual team. This allows us to work seamlessly from protocol design all the way through to analysis and reporting.

ObvioHealth's Numbers

Up to 4x

Faster Recruitment

3 mo ObvioHealth average vs 12 mo benchmark for site-based trials

88%

Retention

average retention vs. 70% benchmark for traditional trials

88%

ePro Compliance

average per study (digital questionnaires, daily ediary, etc.).

Our Client Roster

A. Vogel Logo.
Anatara logo.
Bayer logo.
Danoone Logo.
DSM logo.
entrinsic health logo.
Friesland campina logo.
General mills logo.
Janssen logo.
Lycored logo.
mithra logo.
Mizkan logo.
pfizer logo.
RedHill Biopharma Logo.
Renovia Logo.
Left Carousel Arrow icon.
Right carousel arrow icon.

Leverage Next Gen Solutions in Your Next DCT

Learn More